drugset / Trial / NCT00491868

Clinical Study of R744 to Hemodialysis Patients

NCT00491868

Phase 3 Completed 134 enrolled Chugai Pharmaceutical
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study used as the comparative drug (epoetin beta) will assess the efficacy and safety of intravenous injections of R744 in renal anemia patients on Hemodialysis patients.

Timeline

Start
2007-06
Primary completion
2008-05
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 750 iu Intravenous
Subject epoetin alfa Protein / enzyme biologic 9000 iu Intravenous
Subject methoxy polyethylene glycol-epoetin beta Protein / enzyme biologic 50 ug Intravenous
Subject methoxy polyethylene glycol-epoetin beta Protein / enzyme biologic 250 ug Intravenous

Indications

No indication recorded.